Five Prime Therapeutics, Inc.

Medimmune Limited

Xencor, Inc.

Amplimmune, Inc.

Shannon Marshall

Solomon Langermann

Linda Liu

John R Desjarlais

Lewis T Williams

Kevin Hestir

Rene S Hubert

Stephen Kohl Doberstein

Deborah H Charych

Ernestine A Lee

Stephen D Miller

Elizabeth Bosch

Ali Sadra

Haishan Lin

Cindy Leo

Ge Wu

Aileen Zhou

Justin G P Wong

Dirk Behrens

Robert Forgan Halenbeck

Joseph R Podojil

Min Mei Huang

Thomas Linnemann

Jamal El Yazal

Jeffrey T Finer

Jonathan Zalevsky

Kalyani Penta

Sheng Yao

Srinivas Kothakota

Yan Wang

Thomas Five Prime Therapeutics Inc Linnemann

Justin G Wong

Steven Doberstein

Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1&#x3b2;, TNF-&#x3b1;, TGF-beta, IFN-&#x3b3;, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.

B7-H4 fusion proteins and methods of use thereof

The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages ('TAMs') so as to alter their activity and/or decrease TAM&#x2014;mediated immune suppression.

Anti-B7-H4 antibodies and their uses

The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases.

Antibodies and other molecules that bind B7-H1 and PD-1

Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.

FGFR extracellular domain acidic region muteins

Disclosed is a newly identified secreted molecule, identified herein as 'monocyte, granulocyte, and dendritic cell colony stimulating factor' (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Compositions and methods of use for MGD-CSF in disease treatment

The invention provides pharmaceutical polypeptide compositions that promote proteoglycan synthesis, and promote the activity of chondrocyte cells, thereby treating arthritis. Methods of providing these compositions to treat arthritis are also provided.

Compositions for treating arthritis comprising HG1023575 polypeptide

The invention relates to variants of BMP-7 with improved properties and methods for their use.

BMP-7 variants with improved properties

The present invention relates to novel, soluble, recombinant variants RANKL (Receptor Activator of Nuclear Factor&#x2014;&#x3ba;B Ligand) proteins, which may be expressed solubly invariants that act as RANKL antagonists, and methods for generating the same.

Variants of RANKL protein

The present invention relates to novel, soluble, recombinant RANKL (Receptor Activator of Nuclear Factor&#x2014;&#x3ba;B Ligand) variant proteins which may be expressed solubly in, variants that have substantially reduced binding to OPG, variants that act as RANKL antagonists, and methods for generating the same.

Growing community of inventors

Baltimore, MD, United States of America

Shannon Marshall